Teva Pharmaceutical Industries (TEVJF) EBT (2016 - 2026)

Teva Pharmaceutical Industries has disclosed EBT across 11 years of filings, most recently posting $437.0 million for Q1 2026.

• Quarterly EBT rose 48.64% year-over-year to $437.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 361.19% YoY) and the FY2025 annual result came in at $1.2 billion, up 195.25% from the prior year.
• EBT advanced to $437.0 million in Q1 2026, from $80.0 million in the prior quarter.
• Over five years, EBT peaked at $646.0 million in Q3 2025 and troughed at -$1.2 billion in Q4 2022.
• A 5-year average of -$145.7 million and a median of $64.0 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT sank 774.31% — and 2025, when it surged 299.38%.
• Tracing TEVJF's EBT over 5 years: stood at -$1.2 billion in 2022, then jumped by 142.78% to $507.0 million in 2023, then sank by 148.72% to -$247.0 million in 2024, then jumped by 132.39% to $80.0 million in 2025, then surged by 446.25% to $437.0 million in 2026.
• Business Quant data shows TEVJF's EBT at $437.0 million in Q1 2026, $80.0 million in Q4 2025, and $646.0 million in Q3 2025.